Personalised Medicine Approach For Fluoropyrimidine-based Therapies

Please see new guidance from the UK Chemotherapy Board on ‘Personalised Medicine Approach For Fluoropyrimidine-based Therapies’.

Objective of document: To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.

Full guidance can be accessed HERE or found in our resource center in the BOPA website.

Latest News

By BOPA Committee on 10th August 2020

Clinical Pharmacy Congress – NOW Virtual for 2020

#CPC UPDATE: After careful consideration & in light of the ongoing pandemic, the organisers of @CPCongress have made the decision to postpone CPC 20 to 14/15 May 21 – the…

Read article
By BOPA Committee on 3rd August 2020

Introduction to Oncology Course – AVAILABLE ONLINE NOW

The BOPA Introduction to Oncology Virtual seminar series is now available ONLINE.  As a BOPA member you can watch the seminars anytime you want and also a new QUIZ is…

Read article
By BOPA on 3rd August 2020

What can I expect from a BOPA virtual conference?

Click here for the video from one of the BOPA chairs – Emma Foreman about what to expect.

Read article
By BOPA Abstract deadline EXTENDED TO 9am 10th August 2020 on 27th July 2020

BOPA Abstract deadline EXTENDED TO 9am Monday 10th August 2020

You spoke – we listened The deadline for abstracts for this year’s virtual conference has been extended. Delegates are invited to present results of their clinical and technical work as…

Read article

23rd BOPA Symposium 2020

Friday 9th to Sunday 11th October 2020 – VIRTUAL

Everything you need to know